No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 24
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T22:23:29.236Z. Latest historical point 2024-05-10.
The latest delayed quote for Revelation Biosciences, Inc. (REVB) stock was $0.75 as of Oct 6, 2026, 4:00 PM EDT, down 3.20% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -87.0% · 3-year avg -94.2%/yr · 5-year avg -93.5%/yr
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system.
Biotechnology · San Diego, CA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.88
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.87
vs Estimate
$-0.83
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1REVB | $2.94M | $0.75 | -3.20% | -86.98% | -93.52% | N/A | N/A |
| 2ICCM | $2.86M | $1.27 | -17.53% | -94.60% | -63.05% | N/A | vs REVB |
| 3ADGM | $3.07M | $0.14 | -2.20% | -92.86% | N/A | N/A | vs REVB |
| 4BRTX | $3.14M | $2.27 | +1.34% | -92.40% | -61.44% | -68.97% | vs REVB |
| 5ISPC | $2.69M | $1.07 | +1.90% | -97.66% | -81.14% | N/A | vs REVB |
| 6AEMD | $3.21M | $6.09 | -6.67% | -83.19% | -78.27% | -65.74% | vs REVB |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$17.75
+2259.7% upside
Low
$16.00
Current
$0.75
High
$19.50
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.94 | $-0.88 | $-0.82 | 2 |
| Quarter ending Dec 2026 | $-0.93 | $-0.85 | $-0.77 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-5.19 | $-5.18 | $-5.17 | 2 |
| FY 2027 | $-3.42 | $-2.89 | $-2.36 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $48.97M | $48.97M | $48.97M | 2 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $2.28M |
| $2.28M |
| $2.28M |
| 2 |
